-
Nursing safety is no small matter!
Time of Update: 2021-05-10
Upon review, the court of second instance of the original trial held that: "When the appellant claimed that his relatives were seeking medical treatment at the appellee's place, the appellee failed to fulfill his guardianship duties, causing the patient to fall and died after the rescue was invalid.
-
Roche trastuzumab subcutaneous injection application for listing
Time of Update: 2021-05-10
In the Phase III clinical study code-named SafeHER, the safety and tolerability of Herceptin Hylecta in the adjuvant treatment of Her2-positive breast cancer were consistent with the previous safety features of intravenous Herceptin, and no new safety signals were found.
-
CPX-351 can significantly prolong OS in newly diagnosed high-risk/secondary elderly AML patients: post-mortem analysis of phase 3 study
Time of Update: 2021-05-10
The preliminary results of a key, randomized phase 3 study of newly diagnosed high-risk/secondary elderly AML patients showed that CPX-351 was used for consolidation therapy after induction therapy, and the median overall survival (OS [primary endpoint]; 9.
-
Professor Bai Ou: Inventory of Research Progress in Peripheral T-Cell Lymphoma
Time of Update: 2021-05-10
Yimaitong: Whether patients with peripheral T-cell lymphoma need hematopoietic stem cell transplantation after the first-line treatment is relieved, and whether to choose autologous transplantation or allogeneic transplantation is still controversial.
-
Express | US$900 million to help develop CRISPR gene editing therapy, Vertex renews cooperation
Time of Update: 2021-05-10
CTX001 is a gene editing therapy based on CRISPR/Cas9 technology and is being developed to treat sickle cell anemia (SCD) and transfusion-dependent β-thalassemia syndrome (TDT).
CTX001 is an autologous in vitro CRISPR/Cas9 gene editing therapy under development, currently in clinical trials for the treatment of severe patients with TDT or SCD.
-
Big coffee interview | Professor Chen Wenming: How should patients with multiple myeloma with renal insufficiency be treated?
Time of Update: 2021-05-10
Proteinuria is mainly due to the free light chains secreted by MM cells, which have a small molecular weight and can be excreted in urine to form light chain proteinuria; in addition, free light chains can be concentrated at the distal end of the renal tubule to form a cast and block the distal end Renal tubules, leading to renal tubular renal insufficiency; free light chains may also cause renal amyloidosis or renal light chain deposition disease.
-
Johnson & Johnson's new indication for daratumumab is about to be approved in China
Time of Update: 2021-05-10
Although many progresses have been made in the treatment of multiple myeloma in recent years, most patients still face the problem of relapse or drug resistance.
-
Stones from Other Mountains | Experience Sharing of the Latest Approved PK Software (1): Spanish Experience
Time of Update: 2021-05-10
Recently, a web-based medical application-PK-guided hemophilia A management tool (recombinant human coagulation factor VIII dose calculation software for injection, hereinafter referred to as "PK software") has been approved by the National Medical Products Administration (NMPA) Approved, applicable to hemophilia A patients 16 years and older (45kg and above) receiving rAHF-PFM treatment.
-
Professor Xu Bing: Progress in the treatment of follicular lymphoma|The First National Lymphocytic Disease Academic Conference of the Chinese Medical Association
Time of Update: 2021-05-10
The results of a phase 1/2 study of otuzumab combined with lenalidomide (Glen regimen) in patients with relapsed/refractory FL showed that the median follow-up was 17.
-
How to screen and prevent lymphoma & leukemia?
Time of Update: 2021-05-10
Reference source: Shanghai Anti-Cancer Association "Recommendation for Screening and Prevention of Common Malignant Tumors in Residents" 2021 edition.
-
Professor Kailin Xu: CAR-T has a good effect in treating ALL. Why does it relapse after treatment?
Time of Update: 2021-05-09
The results of most studies have shown that patients who relapse after remission of CD19 CAR-T treatment have poor curative effect after re-infusion of the original CAR-T cell therapy, and the CR rate is less than 30%.
-
FDA approves the first CD19-targeted ADC drug, Linglu Pharmaceuticals owns Chinese rights | Yimai Meng broke the news
Time of Update: 2021-05-09
Big coffee gathered 2021 Nucleic Acid Drug Development Forum Announcement Schedule ★ Nanjing in May 2021 Nucleic Acid Drug Development Forum is about to open April 25, 2021 / Yimaike News eMedClub News/--A few days ago, ADC Therapeutics' CD19 ADC drug loncastuximab tesirine (Lonca, trade name Zynlonta) received accelerated approval from the US FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
-
Professor Liu Qinhua: Analysis of the clinical characteristics of MGRS|Chinese Medical Association First National Lymphocytic Disease Academic Conference
Time of Update: 2021-05-09
In 2019, IKMG redefined MGRS as the clonal proliferation of B cells or plasma cells that did not meet the diagnostic criteria for hematological malignancies, but the monoclonal immunoglobulins produced directly or indirectly caused kidney damage.
Professor Liu Qinhua also pointed out that before treatment, renal function assessment (proteinuria, kidney damage type, urine protein 24h quantification, etc.
-
Chinese patients with hemophilia A and inhibitors: National real-world study data analysis and follow-up results
Time of Update: 2021-05-09
On February 22, the team of Professor Yang Renchi from the Hospital of Hematology of the Chinese Academy of Medical Sciences officially published in the British Journal of Haematology the results of a real-world study on Chinese patients with hemophilia A and inhibitors, revealing the current status of patients with HA and inhibitors in China.
-
Professor Li Jian: Progress in Diagnosis and Treatment of Fahrenheit Macroglobulinemia|The First National Lymphocytic Disease Academic Conference of the Chinese Medical Association
Time of Update: 2021-05-09
WM diagnosis method Professor Li Jian said that the core elements of WM diagnosis include 1) positive serum monoclonal IgM; 2) the presence of CD5-CD10-monoclonal B cells in the bone marrow; 3) the presence of WM-related clinical symptoms.
Later, Professor Li Jian emphasized that attention should be paid to the detection method and false negative rate of MYD88.
-
Reduced from several injections a week to an average of 1 time!
Time of Update: 2021-05-09
▎ WuXi AppTec content team editor April 23, according to the official website of China National Medical Products Administration (NMPA), Sanofi (Sanofi) company's injection of Ainocoagulin α (ie recombinant human coagulation factor IX-Fc for injection) The fusion protein, trade name: Saijiu Ning®, English trade name Alprolix®) was officially approved for marketing applications, used for bleeding control, routine prevention, and perioperative bleeding management in adults and children with hemophilia B.
-
Professor Zou Dehui: Under the wave of precision, the treatment and prospects of classic Hodgkin's lymphoma
Time of Update: 2021-05-09
For young patients with R/R cHL who are suitable for transplantation, after salvage treatment is used to obtain disease remission, sequential autologous hematopoietic stem cell transplantation consolidation therapy, about 50% of patients can again achieve long-term survival.
-
Prof. Xu Wei: Current status and resistance mechanism of BCL-2 inhibitors in CLL
Time of Update: 2021-05-09
In the phase III clinical trial of the MURANO study, 11 patients also received Venecla treatment after disease progression, and 6 patients achieved remission, with an objective remission rate (ORR) of 55%.
-
The results of the Altrobopar study are gratifying: Professor Tang Yongmin & Professor Song Hua look forward to the prospects of SAA treatment in children
Time of Update: 2021-05-09
Yimaitong: A study conducted by the Children's Hospital of Zhejiang University School of Medicine explored the efficacy of the standard IST regimen combined with the thrombopoietin receptor agonist etrobopar in children with SAA.
-
Professor Huang Haiwen: The position of allogeneic transplantation in the treatment of lymphoma in the era of new drugs and immunotherapy
Time of Update: 2021-05-09
Allo-HCT is usually used in patients with diffuse large B-cell lymphoma (DLBCL) that relapse after autologous hematopoietic stem cell transplantation (Auto-HCT), patients with diseases that do not respond to multiple treatments, and high-risk genomes, such as double-hit Patients with lymphoma or early recurrence (1 year from diagnosis).
